Vyvgart
What Vyvgart is used for
Vyvgart is indicated as- an add-on to standard therapy for the treatment of adult patients with generalised Myasthenia Gravis (gMG) who are antiacetylcholine receptor (AChR) antibody positive.- monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Vyvgart
- Active substance
- efgartigimod alfa
- Disease area
- Myasthenia Gravis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Medicine group
- Immunosuppressants
- ATC code
- L04AA58
- Marketing authorisation holder
- Argenx
- Authorised in the EU since
- 2022
Official information
In the USA
Same active substance: VYVGART Hytrulo, Vyvgart
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Vyvgart used for?
Vyvgart is indicated as- an add-on to standard therapy for the treatment of adult patients with generalised Myasthenia Gravis (gMG) who are antiacetylcholine receptor (AChR) antibody positive.- monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins.
What is the active substance in Vyvgart?
Vyvgart contains efgartigimod alfa.
Who makes Vyvgart?
The EU marketing authorisation holder is Argenx.
Is Vyvgart an orphan medicine?
Yes. Vyvgart is designated an orphan medicine in the EU, for a rare disease (Myasthenia Gravis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU